Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Andrew Walding
Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer
European Journal of Cancer
Cancer Research
Oncology
Related publications
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
The Impact of Initial Gefitinib or Erlotinib Versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Clinical Cancer Research
Cancer Research
Oncology
Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib
ESMO Open
Cancer Research
Oncology
Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
ILD During Erlotinib and Gefitinib Treatment in Japanese Patients With Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer
Current Oncology
Oncology
Management of Patients With Advanced Non-Small Cell Lung Cancer: Role of Gefitinib
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib
Oncology Letters
Cancer Research
Oncology
